ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 355,37
1,00%
Dow Jones
42 992,21
-0,77%
DAX
19 984,32
0,74%
Brent Oil
73,605
-0,03%
Bitcoin
93 499,39
-0,02%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ

  6. Inhibikase Therapeutics Inc (IKT) Cours

Inhibikase Therapeutics Inc

Inhibikase Therapeutics Inc (IKT)

NASDAQ
3,05
-0,01
(-0,33%)
À la fermeture: 30 Décembre 10:00PM
Retardé de 15 minutes
2,85
-0,20
( -6,56% )
Après les heures de négociation: 11:29PM
Retardé de 15 minutes

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Premium

Statistiques et détails clés

Dernier
2,85
Prix Achat
2,81
Prix Vente
6,00
Volume échangé
58 353
2,9072 Fourchette du Jour 3,12
1,12 Plage de 52 semaines 4,20
Cap du marché
191,499M
Clôture Veille
3,06
Ouverture
2,9072
Dernière Transaction
3
@
2.92
Dernière heure de transaction
01:05:08
Volume financier
US$ 175 227
VWAP
3,0029
Volume moyen (3 m)
690 001
Actions en circulation
67 192 570
Rendement du Dividende
-
Ratio Cours sur Bénéfices
-10,81
Bénéfice par action (BPA)
-0,28
Chiffre d'affairess
261k
Bénéfice net
-19,03M

À propos de Inhibikase Therapeutics Inc

Inhibikase Therapeutics Inc is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders. Its multi-therapeutic pipeline focuses on neurodegeneration and its lead program for IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, intends to trea... Inhibikase Therapeutics Inc is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders. Its multi-therapeutic pipeline focuses on neurodegeneration and its lead program for IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, intends to treat Parkinson's disease inside and outside the brain. The company is performing its Phase I, randomized single ascending dose and multiple ascending dose, study to determine the safety, tolerability and pharmacokinetics of IkT-148009 in older and healthy subjects. It is also advancing a novel drug delivery platform to treat certain forms of cancer at the same time as it is developing novel drugs for the treatment of neurodegenerative disease. Show more

Secteur
Biological Pds,ex Diagnstics
Industrie
Biological Pds,ex Diagnstics
Site Web
www.inhibikase.com
Siège social
Wilmington, Delaware, USA
Fondé
-
Inhibikase Therapeutics Inc est coté dans le secteur Biological Pds,ex Diagnstics de la NASDAQ avec le ticker IKT. Le dernier cours de clôture d'Inhibikase Therapeutics était de US$3,06. Au cours de la dernière année, les actions de Inhibikase Therapeutics ont été négociées dans une fourchette de prix de US$ 1,12 à US$ 4,20.

Inhibikase Therapeutics compte actuellement 67 192 570 actions en circulation. La capitalisation boursière d'Inhibikase Therapeutics est de US$205,61 million. Inhibikase Therapeutics a un ratio cours/bénéfice (ratio PE) de -10.81.

IKT Dernières nouvelles

Plus de nouvelles

Form EFFECT - Notice of Effectiveness

06 Décembre 2024
Edgar (US Regulatory)

Form 8-K - Current report

05 Décembre 2024
Edgar (US Regulatory)

Form 424B3 - Prospectus [Rule 424(b)(3)]

05 Décembre 2024
Edgar (US Regulatory)

Form S-3/A - Registration statement under Securities Act of 1933: [Amend]

03 Décembre 2024
Edgar (US Regulatory)

Form S-3 - Registration statement under Securities Act of 1933

18 Novembre 2024
Edgar (US Regulatory)

Form DEF 14A - Other definitive proxy statements

18 Novembre 2024
Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

14 Novembre 2024
Edgar (US Regulatory)

Form PRE 14A - Other preliminary proxy statements

08 Novembre 2024
Edgar (US Regulatory)

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

28 Octobre 2024
Edgar (US Regulatory)

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

28 Octobre 2024
Edgar (US Regulatory)
PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
1-0.28-8.945686900963.133.52.855360933.16624234CS
40.093.260869565222.764.22.574714823.32621893CS
121.57122.656251.284.21.1466900012.0360411CS
261.45103.5714285711.44.21.123331142.0100861CS
521.66139.4957983191.194.21.122174532.06999699CS
156-6.63-69.93670886089.4810.80.791977383.51513048CS
260-61.17-95.548266166864.0270.80.792388909.58765206CS

IKT - Frequently Asked Questions (FAQ)

What is the current Inhibikase Therapeutics share price?
The current share price of Inhibikase Therapeutics is US$ 2,85
How many Inhibikase Therapeutics shares are in issue?
Inhibikase Therapeutics has 67 192 570 shares in issue
What is the market cap of Inhibikase Therapeutics?
The market capitalisation of Inhibikase Therapeutics is USD 205,61M
What is the 1 year trading range for Inhibikase Therapeutics share price?
Inhibikase Therapeutics has traded in the range of US$ 1,12 to US$ 4,20 during the past year
What is the PE ratio of Inhibikase Therapeutics?
The price to earnings ratio of Inhibikase Therapeutics is -10,81
What is the cash to sales ratio of Inhibikase Therapeutics?
The cash to sales ratio of Inhibikase Therapeutics is 784,62
What is the reporting currency for Inhibikase Therapeutics?
Inhibikase Therapeutics reports financial results in USD
What is the latest annual turnover for Inhibikase Therapeutics?
The latest annual turnover of Inhibikase Therapeutics is USD 261k
What is the latest annual profit for Inhibikase Therapeutics?
The latest annual profit of Inhibikase Therapeutics is USD -19,03M
What is the registered address of Inhibikase Therapeutics?
The registered address for Inhibikase Therapeutics is 1313 N MARKET ST STE 5100, SUITE 101, WILMINGTON, DELAWARE, 19801
What is the Inhibikase Therapeutics website address?
The website address for Inhibikase Therapeutics is www.inhibikase.com
Which industry sector does Inhibikase Therapeutics operate in?
Inhibikase Therapeutics operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
VINCVincerx Inc
US$ 0,32
(64,95%)
23,04M
AERTAeries Technology Inc
US$ 1,39
(58,51%)
1,96M
CCTGCCSC Technology International Holdings Ltd
US$ 2,45
(49,39%)
3,11M
ARTWArts Way Manufacturing Co Inc
US$ 3,28
(34,43%)
242,28k
VRPXVirpax Pharmaceuticals Inc
US$ 0,501
(22,20%)
2,26M
LITMSnow Lake Resources Ltd
US$ 1,10
(-31,25%)
9,69M
XAIRBeyond Air Inc
US$ 0,38
(-13,64%)
1,9M
SHMDSCHMID Group NV
US$ 2,75
(-12,42%)
24,28k
COEPCoeptis Therapeutics Holdings Inc
US$ 0,1601
(-12,13%)
340,97k
AVGRAvinger Inc
US$ 0,85
(-11,92%)
271,51k
VINCVincerx Inc
US$ 0,32
(64,95%)
23,04M
CEROCERo Therapeutics Holdings Inc
US$ 0,0628
(4,67%)
15,27M
XTIAXTI Aerospace Inc
US$ 0,0414
(4,81%)
13,19M
LITMSnow Lake Resources Ltd
US$ 1,10
(-31,25%)
9,69M
INTZIntrusion Inc
US$ 1,94
(-10,19%)
7,78M

Forums

Afficher les forums
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

NASDAQ
IKT
Inhibikase Therapeutics
BIT
XT01
Xtrackers Treasuries Ult...
BITMOT
809321
Oat Green Bond Tf 1,75% ...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés